US5916891A
(en)
*
|
1992-01-13 |
1999-06-29 |
Smithkline Beecham Corporation |
Pyrimidinyl imidazoles
|
WO1996021654A1
(en)
*
|
1995-01-12 |
1996-07-18 |
Smithkline Beecham Corporation |
Novel compounds
|
IL118544A
(en)
|
1995-06-07 |
2001-08-08 |
Smithkline Beecham Corp |
History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
|
US5739143A
(en)
*
|
1995-06-07 |
1998-04-14 |
Smithkline Beecham Corporation |
Imidazole compounds and compositions
|
US6369068B1
(en)
|
1995-06-07 |
2002-04-09 |
Smithkline Beecham Corporation |
Amino substituted pyrimidine containing compounds
|
ZA9610687B
(en)
|
1995-12-22 |
1997-09-29 |
Smithkline Beecham Corp |
Novel synthesis.
|
KR19990077164A
(ko)
*
|
1996-01-11 |
1999-10-25 |
스티븐 베네티아너 |
신규 치환된 이미다졸 화합물
|
US6046208A
(en)
*
|
1996-01-11 |
2000-04-04 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
AP9700912A0
(en)
*
|
1996-01-11 |
1997-01-31 |
Smithkline Beecham Corp |
Novel cycloalkyl substituted imidazoles
|
ZA97175B
(en)
*
|
1996-01-11 |
1997-11-04 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds.
|
WO1997032583A1
(en)
*
|
1996-03-08 |
1997-09-12 |
Smithkline Beecham Corporation |
Use of csaidtm compounds as inhibitors of angiogenesis
|
WO1997035855A1
(en)
*
|
1996-03-25 |
1997-10-02 |
Smithkline Beecham Corporation |
Novel treatment for cns injuries
|
WO1997035856A1
(en)
*
|
1996-03-25 |
1997-10-02 |
Smithkline Beecham Corporation |
Novel treatment for cns injuries
|
WO1998007425A1
(en)
|
1996-08-21 |
1998-02-26 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
WO1998016230A1
(en)
*
|
1996-10-17 |
1998-04-23 |
Smithkline Beecham Corporation |
Methods for reversibly inhibiting myelopoiesis in mammalian tissue
|
ZA9711092B
(en)
*
|
1996-12-11 |
1999-07-22 |
Smithkline Beecham Corp |
Novel compounds.
|
US6020357A
(en)
*
|
1996-12-23 |
2000-02-01 |
Dupont Pharmaceuticals Company |
Nitrogen containing heteroaromatics as factor Xa inhibitors
|
US6548512B1
(en)
|
1996-12-23 |
2003-04-15 |
Bristol-Myers Squibb Pharma Company |
Nitrogen containing heteroaromatics as factor Xa inhibitors
|
US5929076A
(en)
*
|
1997-01-10 |
1999-07-27 |
Smithkline Beecham Corporation |
Cycloalkyl substituted imidazoles
|
AU7726898A
(en)
*
|
1997-05-22 |
1998-12-11 |
G.D. Searle & Co. |
Pyrazole derivatives as p38 kinase inhibitors
|
US6979686B1
(en)
|
2001-12-07 |
2005-12-27 |
Pharmacia Corporation |
Substituted pyrazoles as p38 kinase inhibitors
|
US6514977B1
(en)
|
1997-05-22 |
2003-02-04 |
G.D. Searle & Company |
Substituted pyrazoles as p38 kinase inhibitors
|
CA2294057A1
(en)
|
1997-06-13 |
1998-12-17 |
Smithkline Beecham Corporation |
Novel pyrazole and pyrazoline substituted compounds
|
US6610695B1
(en)
|
1997-06-19 |
2003-08-26 |
Smithkline Beecham Corporation |
Aryloxy substituted pyrimidine imidazole compounds
|
US6339099B1
(en)
|
1997-06-20 |
2002-01-15 |
Dupont Pharmaceuticals Company |
Guanidine mimics as factor Xa inhibitors
|
AR016294A1
(es)
*
|
1997-07-02 |
2001-07-04 |
Smithkline Beecham Corp |
Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
|
TW517055B
(en)
|
1997-07-02 |
2003-01-11 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds
|
US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
US6562832B1
(en)
|
1997-07-02 |
2003-05-13 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
US6489325B1
(en)
|
1998-07-01 |
2002-12-03 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
WO1999001452A1
(en)
|
1997-07-02 |
1999-01-14 |
Smithkline Beecham Corporation |
Novel cycloalkyl substituted imidazoles
|
CA2306077A1
(en)
|
1997-10-08 |
1999-04-15 |
Smithkline Beecham Corporation |
Novel cycloalkenyl substituted compounds
|
EP1021173A1
(en)
*
|
1997-10-10 |
2000-07-26 |
Imperial College Innovations Limited |
Use of csaid?tm compounds for the management of uterine contractions
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
CA2310046A1
(en)
*
|
1997-11-14 |
1999-05-27 |
Sankyo Company Limited |
Pyridylpyrrole derivatives
|
US6335340B1
(en)
|
1997-12-19 |
2002-01-01 |
Smithkline Beecham Corporation |
compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
|
US20080300281A1
(en)
*
|
1997-12-22 |
2008-12-04 |
Jacques Dumas |
Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
|
US7517880B2
(en)
*
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
US6448257B1
(en)
|
1998-05-22 |
2002-09-10 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
US6130235A
(en)
*
|
1998-05-22 |
2000-10-10 |
Scios Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
US6867209B1
(en)
|
1998-05-22 |
2005-03-15 |
Scios, Inc. |
Indole-type derivatives as inhibitors of p38 kinase
|
US6340685B1
(en)
|
1998-05-22 |
2002-01-22 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
CZ20004339A3
(cs)
|
1998-05-22 |
2001-10-17 |
Smithkline Beecham Corporation |
Nové 2-alkylem substituované imidazolové sloučeniny
|
US6589954B1
(en)
|
1998-05-22 |
2003-07-08 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
US6858617B2
(en)
|
1998-05-26 |
2005-02-22 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
US6207687B1
(en)
*
|
1998-07-31 |
2001-03-27 |
Merck & Co., Inc. |
Substituted imidazoles having cytokine inhibitory activity
|
ES2221426T3
(es)
*
|
1998-08-20 |
2004-12-16 |
Smithkline Beecham Corporation |
Nuevos compuestos de triazol sustituidos.
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
EP1107758A2
(en)
|
1998-08-28 |
2001-06-20 |
Scios Inc. |
Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
|
WO2000012485A1
(en)
|
1998-08-29 |
2000-03-09 |
Astrazeneca Ab |
Pyrimidine compounds
|
EP1107958B1
(en)
|
1998-08-29 |
2006-08-16 |
AstraZeneca AB |
Pyrimidine compounds
|
AU6476599A
(en)
*
|
1998-11-03 |
2000-05-22 |
Novartis Ag |
Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
|
AU1909200A
(en)
*
|
1998-11-04 |
2000-05-22 |
Smithkline Beecham Corporation |
Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
|
US6239279B1
(en)
|
1998-12-16 |
2001-05-29 |
Smithkline Beecham Corporation |
Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
ES2377847T3
(es)
|
1999-01-13 |
2012-04-02 |
Bayer Healthcare Llc |
Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
CA2360934A1
(en)
|
1999-02-22 |
2000-08-31 |
Lin-Hua Zhang |
Polycyclo heterocyclic derivatives as antiinflammatory agents
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
NZ514711A
(en)
|
1999-03-12 |
2004-02-27 |
Boehringer Ingelheim Pharma |
Compounds useful as anti-inflammatory agents
|
MXPA01009077A
(es)
|
1999-03-12 |
2002-03-27 |
Boehringer Ingelheim Pharma |
Composiciones heterociclicos aromaticos como agentes anti-inflamatorios.
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
CO5170501A1
(es)
*
|
1999-04-14 |
2002-06-27 |
Novartis Ag |
AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
|
US6930101B1
(en)
|
1999-05-17 |
2005-08-16 |
The Regents Of The University Of California |
Thiazolopyrimidines useful as TNFα inhibitors
|
IL146309A
(en)
|
1999-05-21 |
2008-03-20 |
Scios Inc |
Derivatives of the indole type and pharmaceutical preparations containing them as inhibitors of kinase p38
|
ATE312823T1
(de)
|
1999-07-09 |
2005-12-15 |
Boehringer Ingelheim Pharma |
Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
|
US7122666B2
(en)
*
|
1999-07-21 |
2006-10-17 |
Sankyo Company, Limited |
Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
|
GB9919778D0
(en)
*
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
US6541477B2
(en)
|
1999-08-27 |
2003-04-01 |
Scios, Inc. |
Inhibitors of p38-a kinase
|
BR0014041A
(pt)
*
|
1999-09-17 |
2003-07-15 |
Smithkline Beecham Corp |
Utilização de csaids em infecção por rinovìrus
|
ATE311385T1
(de)
*
|
1999-10-27 |
2005-12-15 |
Novartis Pharma Gmbh |
Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
|
US7053099B1
(en)
|
1999-11-23 |
2006-05-30 |
Smithkline Beecham Corporation |
3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
|
WO2001038313A1
(en)
|
1999-11-23 |
2001-05-31 |
Smithkline Beecham Corporation |
3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS
|
ATE296809T1
(de)
*
|
1999-11-23 |
2005-06-15 |
Smithkline Beecham Corp |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
|
US6759410B1
(en)
*
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
ES2236007T3
(es)
*
|
1999-12-08 |
2005-07-16 |
Pharmacia Corporation |
Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
BR0109643A
(pt)
*
|
2000-03-30 |
2003-04-22 |
Shionogi & Co |
Processo sintético e forma de cristal de derivados condensados da imidazopiridina
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
US20020128267A1
(en)
*
|
2000-07-13 |
2002-09-12 |
Rebanta Bandyopadhyay |
Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders
|
PE20020506A1
(es)
*
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
DK1333833T3
(da)
*
|
2000-10-23 |
2011-12-12 |
Glaxosmithkline Llc |
Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
|
US6867300B2
(en)
*
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
US6670357B2
(en)
*
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
CA2429258A1
(en)
|
2000-11-20 |
2002-06-13 |
Scios Inc. |
Piperidine/piperazine-type inhibitors of p38 kinase
|
JP2004536779A
(ja)
*
|
2000-11-20 |
2004-12-09 |
サイオス インコーポレイテッド |
p38キナーゼのインドール型阻害剤
|
US6821966B2
(en)
|
2000-11-20 |
2004-11-23 |
Scios, Inc. |
Inhibitors of p38 kinase
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
US7199124B2
(en)
*
|
2001-02-02 |
2007-04-03 |
Takeda Pharmaceutical Company Limited |
JNK inhibitor
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
EP1370557B1
(en)
*
|
2001-03-09 |
2005-11-16 |
Pfizer Products Inc. |
Benzimidazole anti-inflammatory compounds
|
US7695736B2
(en)
|
2001-04-03 |
2010-04-13 |
Pfizer Inc. |
Reconstitutable parenteral composition
|
WO2002094267A1
(fr)
*
|
2001-05-24 |
2002-11-28 |
Sankyo Company, Limited |
Preparation pharmaceutique pour prevenir ou traiter l'arthrite
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
US7076539B2
(en)
*
|
2001-07-30 |
2006-07-11 |
Hewlett-Packard Development Company, L.P. |
Network connectivity establishment at user log-in
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
GB0124933D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124936D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124938D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124932D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124931D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124934D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124939D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124941D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
CA2461100C
(en)
*
|
2001-10-22 |
2009-12-01 |
Tanabe Seiyaku Co., Ltd. |
4-imidazolin-2-one compounds
|
ATE420671T1
(de)
*
|
2001-10-25 |
2009-01-15 |
Univ Connecticut |
Fibroinzusammensetzungen und verfahren zu deren herstellung
|
DE10294485T5
(de)
*
|
2001-10-29 |
2004-04-29 |
DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung |
Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind
|
AU2003209119A1
(en)
|
2002-02-11 |
2003-09-04 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
DK1474395T3
(da)
*
|
2002-02-12 |
2008-02-11 |
Smithkline Beecham Corp |
Nicotinamidderivater, der er nyttige som p38-inhibitorer
|
AU2003213806A1
(en)
|
2002-02-25 |
2003-09-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
EP1490354A1
(en)
|
2002-03-09 |
2004-12-29 |
Astrazeneca AB |
4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
AR039241A1
(es)
*
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
EP1497019B1
(en)
|
2002-04-23 |
2015-05-20 |
Bristol-Myers Squibb Company |
Pyrrolo-triazine aniline compounds useful as kinase inhibitors
|
EP1707205A2
(en)
|
2002-07-09 |
2006-10-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
ATE343572T1
(de)
|
2002-08-09 |
2006-11-15 |
Lilly Co Eli |
Benzimidazole und benzothiazole als inhibitoren der map-kinase
|
AU2003262911A1
(en)
|
2002-08-29 |
2004-03-19 |
Scios Inc. |
Methods of promoting osteogenesis
|
CA2497408A1
(en)
|
2002-09-03 |
2004-03-18 |
Sarvajit Chakravarty |
Indole-type derivatives as inhibitors of p38 kinase
|
UA80295C2
(en)
*
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Pyrazolopyridines and using the same
|
UA80296C2
(en)
*
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Imidazolopyridines and methods of making and using the same
|
MXPA05003817A
(es)
|
2002-10-09 |
2005-07-13 |
Scios Inc |
Derivados de azaindoles como inhibidores de p38 quinasa.
|
CL2004000234A1
(es)
*
|
2003-02-12 |
2005-04-15 |
Biogen Idec Inc |
Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
GB0308186D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308185D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308201D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308466D0
(en)
*
|
2003-04-11 |
2003-05-21 |
Novartis Ag |
Organic compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
DK1626714T3
(da)
|
2003-05-20 |
2007-10-15 |
Bayer Pharmaceuticals Corp |
Dirarylurinstoffer mod sygdomme medieret af PDGFR
|
CA2528438A1
(en)
*
|
2003-06-03 |
2005-01-06 |
Novartis Ag |
P-38 inhibitors
|
PT1641764E
(pt)
|
2003-06-26 |
2011-10-27 |
Novartis Ag |
Inibidores de p38 quinase a base de heterociclo de 5 elementos
|
US7105467B2
(en)
*
|
2003-07-08 |
2006-09-12 |
Pharmacore, Inc. |
Nickel catalyzed cross-coupling reactions between organomagnesium compounds and anisole derivatives
|
RS52625B
(en)
|
2003-07-23 |
2013-06-28 |
Bayer Healthcare Llc |
FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
|
ES2315703T3
(es)
*
|
2003-07-25 |
2009-04-01 |
Novartis Ag |
Inhibidores de la quinasa p-38.
|
GB0318814D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
WO2005030091A2
(en)
|
2003-09-25 |
2005-04-07 |
Scios Inc. |
Stents and intra-luminal prostheses containing map kinase inhibitors
|
US7232824B2
(en)
|
2003-09-30 |
2007-06-19 |
Scios, Inc. |
Quinazoline derivatives as medicaments
|
US7419978B2
(en)
*
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
US7183305B2
(en)
*
|
2003-11-11 |
2007-02-27 |
Allergan, Inc. |
Process for the synthesis of imidazoles
|
US7880017B2
(en)
*
|
2003-11-11 |
2011-02-01 |
Allergan, Inc. |
Process for the synthesis of imidazoles
|
US7105707B2
(en)
*
|
2003-12-17 |
2006-09-12 |
Pharmacore, Inc. |
Process for preparing alkynyl-substituted aromatic and heterocyclic compounds
|
GB0402143D0
(en)
*
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
KR100793479B1
(ko)
*
|
2004-04-28 |
2008-01-14 |
다나베 미츠비시 세이야꾸 가부시키가이샤 |
염증성 질환을 치료하기 위한 p38 MAP- 키나제억제제로서의4-2-(시클로알킬아미노)피리딘-4-일-(페닐)-이미다졸린-2-온 유도체
|
MY143245A
(en)
*
|
2004-04-28 |
2011-04-15 |
Mitsubishi Tanabe Pharma Corp |
4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
|
EP1751139B1
(en)
*
|
2004-04-30 |
2011-07-27 |
Bayer HealthCare LLC |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
US7504521B2
(en)
*
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
US7148348B2
(en)
|
2004-08-12 |
2006-12-12 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
US20080051416A1
(en)
*
|
2004-10-05 |
2008-02-28 |
Smithkline Beecham Corporation |
Novel Compounds
|
JP2006182763A
(ja)
*
|
2004-12-03 |
2006-07-13 |
Daiso Co Ltd |
α,β−不飽和エステルの製法
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
EP1676574A3
(en)
|
2004-12-30 |
2006-07-26 |
Johnson & Johnson Vision Care, Inc. |
Methods for promoting survival of transplanted tissues and cells
|
US20060178388A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
GB0504753D0
(en)
*
|
2005-03-08 |
2005-04-13 |
Astrazeneca Ab |
Chemical compounds
|
MY145281A
(en)
|
2005-03-25 |
2012-01-13 |
Glaxo Group Ltd |
Novel compounds
|
CA2603163A1
(en)
*
|
2005-03-25 |
2006-10-05 |
Glaxo Group Limited |
Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
|
US20060235020A1
(en)
*
|
2005-04-18 |
2006-10-19 |
Soojin Kim |
Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
|
GB0512429D0
(en)
*
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
US7473784B2
(en)
*
|
2005-08-01 |
2009-01-06 |
Bristol-Myers Squibb Company |
Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
|
DE102005048072A1
(de)
*
|
2005-09-24 |
2007-04-05 |
Bayer Cropscience Ag |
Thiazole als Fungizide
|
BRPI0616722A2
(pt)
|
2005-09-30 |
2012-12-25 |
Astrazeneca Ab |
composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas
|
DE102006001161A1
(de)
*
|
2006-01-06 |
2007-07-12 |
Qiagen Gmbh |
Verfahren zum Nachweis von Cytosin-Methylierungen
|
CN101395158A
(zh)
*
|
2006-03-07 |
2009-03-25 |
百时美施贵宝公司 |
可作为激酶抑制剂的吡咯并三嗪苯胺前体药物化合物
|
MX2008013130A
(es)
|
2006-04-12 |
2008-11-19 |
Probiodrug Ag |
Inhibidores de enzima.
|
CN101616667A
(zh)
|
2006-10-27 |
2009-12-30 |
百时美施贵宝公司 |
可用作激酶抑制剂的杂环酰胺化合物
|
US7943617B2
(en)
*
|
2006-11-27 |
2011-05-17 |
Bristol-Myers Squibb Company |
Heterobicyclic compounds useful as kinase inhibitors
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
EP2307411B1
(en)
*
|
2008-06-20 |
2014-01-01 |
Bristol-Myers Squibb Company |
Triazolopyridine compounds useful as kinase inhibitors
|
CN102131805A
(zh)
|
2008-06-20 |
2011-07-20 |
百时美施贵宝公司 |
用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物
|
WO2012031057A1
(en)
|
2010-09-01 |
2012-03-08 |
Bristol-Myers Squibb Company |
Bms- 582949 for the treatment of resistant rheumatic disease
|
US10722513B2
(en)
|
2015-03-23 |
2020-07-28 |
The University Of Melbourne |
Treatment of respiratory diseases
|
WO2018201192A1
(en)
*
|
2017-05-03 |
2018-11-08 |
The University Of Melbourne |
Compounds for the treatment of respiratory diseases
|
WO2019071147A1
(en)
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
CN113272298A
(zh)
*
|
2018-11-07 |
2021-08-17 |
墨尔本大学 |
用于治疗呼吸系统疾病的化合物和组合物
|
CA3209491A1
(en)
|
2021-03-15 |
2022-09-22 |
Saul Yedgar |
Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease
|